Asedebart is a monoclonal antibody that binds ACTH, the pituitary signal driving chronic cortisol excess in Cushing's disease, a rare neuroendocrine disorder, and acts upstream of every approved therapy.
Lundbeck's asedebart, an experimental monoclonal antibody that binds and neutralizes the pituitary hormone ACTH, drove cortisol into the normal range for 7 of 8 evaluable adults with Cushing's disease in an open-label Phase II study, the company said at the Endocrine Society's ENDO 2026 meeting in Chicago. The result is a striking early signal for a mechanism that acts upstream of every approved therapy for the condition, but it also reflects the limits of the data: eight evaluable patients, no comparator arm, sponsor framing, and no reported durability off the individualized IV dose-titration phase.
Cushing's disease is a rare neuroendocrine disorder in which a pituitary adenoma pumps out excess adrenocorticotropic hormone, or ACTH, which in turn drives the adrenal glands to overproduce cortisol. The chronic cortisol excess drives the metabolic, cardiovascular, musculoskeletal, and neuropsychiatric features of the disease and raises mortality when untreated. Approved drugs for the condition, including pasireotide, osilodrostat, levoketoconazole, and the glucocorticoid receptor antagonist mifepristone, work downstream, either by suppressing cortisol synthesis in the adrenal glands or by blocking cortisol's action at its receptor. Asedebart instead aims at the signal that starts the cascade. It is a humanized antibody designed to bind circulating ACTH and prevent it from engaging the melanocortin 2 receptor, the protein on the adrenal cortex that the pituitary hormone normally uses to tell the adrenal glands to make cortisol.
The interim readout came from Part A of an ongoing multi-center, open-label, dose-titration Phase II in adults with ACTH-driven Cushing's disease of pituitary origin. At data cut-off, 12 patients had enrolled, 9 had begun intravenous dosing, 8 of those 9 had completed individualized IV dose titration, and 7 of those 8 evaluable patients reached the protocol's biochemical target: urinary free cortisol, or UFC, at or below the upper limit of normal (Lundbeck press release via PR Newswire). The trial is independently registered as NCT06471829, "A Trial of Lu AG13909 in Adult Participants With Cushing's Disease", a Phase 2, single-arm, open-label study with a planned enrollment of 18 patients and a primary completion date of September 2026.
The safety picture in the release is more textured than the company's "no new safety signals" line. Treatment-emergent adverse events were reported in all 12 enrolled patients. Three patients experienced serious adverse events, including one death that the company described as unrelated to the drug. Two patients had events consistent with glucocorticoid deficiency, the predictable consequence of abruptly turning off ACTH drive in a cortisol-exposed body, and were managed with short-term hydrocortisone. No hypersensitivity events were reported. ACTH neutralization in a cortisol-dependent patient is a deliberate biochemical maneuver, and the clinical question is not whether adrenal insufficiency can occur. It is how often, how severely, and how it is handled in routine use.
The presentation is also a positioning move for Lundbeck. The company, long identified with central nervous system drugs, is framing asedebart as a neurohormonal extension of that heritage into rare endocrine disease, anchored by a quote from Johan Luthman, executive vice president and head of R&D, calling direct ACTH neutralization "a novel therapeutic approach in Cushing's disease, a neuroendocrine condition where major unmet medical needs remain" (Lundbeck press release via PR Newswire). The same release notes that asedebart already holds orphan drug designation for congenital adrenal hyperplasia in the European Union and United States, and for both Cushing's disease and CAH in Japan.
What to watch next is concrete. Part B of the same Phase II is testing a subcutaneous formulation, which would matter for any chronic-dosing story but is a development plan, not a clinical result. The data set still has to answer whether UFC normalization persists off the IV titration phase, whether symptom and comorbidity outcomes (the things patients actually feel) move alongside the biochemistry, how chronic ACTH neutralization affects the adrenal axis and immunogenicity over time, and whether a future randomized study will benchmark asedebart against pasireotide or osilodrostat rather than against nothing. The 7-of-8 number is real, and the mechanism is genuinely upstream. Neither, on its own, is the same as a treatment that changes practice.